References
- Allen J. G., Alderson J., Galloway D. B., Hallett C. The effect of midazolam (Hypnovelr`) administration on antipyrine pharmacokinetics in humans. Xenobiotica 1987; 17: 875–879
- Allen J. G., Galloway D. B., Ehsanullah R. S. B., Ruane R. J. The effect of bromazepam (Lexotan) administration on antipyrine pharmacokinetics in humans. Xenobiotica 1984; 14: 321–326
- Crevoisier Ch., Ziegler W. H., Eckert M., Heizmann P. Relationships between plasma concentration and effect of midazolam after oral and intravenous administration. British Journal of Clinical Pharmacology 1983; 16: 51s–61s
- Danhof M., Krom D. P., Breimer D. D. Studies on the different metabolic pathways of antipyrine in rats; influence of phenobarbital and 3-methylcholanthrene treatment. Xenobiotica 1979; 9: 695–702
- Fukazawa H., Iwase H., Ichishita H., Takizawa T., Shimizu H. Effect of chronic administration of bromazepam on its blood level profile and on the hepatic drug metabolising enzymes in the rat. Drug Metabolism and Disposition 1975; 3: 235–244
- Heizmann P., Eckert M., Ziegler W. H. Pharmacokinetics and bioavailability of midazolam in man. British Journal of Clinical Pharmacology 1983; 16: 43s–49s
- Heizmann P., Ziegler W. H. Excretion of 14C-midazolam in humans following oral dosing. Arzneimittel-Forschung 1981; 31: 2220–2223
- Orme M., Breckenridge A., Brooks R. V. Interactions of benzodiazepines with waferin. British Medical Journal 1972; 3: 611–614
- Perucca E. Clinical consequences of microsomal enzyme induction by anti-epileptic drugs. Pharmaceutical Therapeutics 1978; 2: 285–314
- Tomisawa H., Satoh K., Sakata H., Ichimoto N., Ichihara I., Fukazawa H., Tateishi M. Pharmacokinetic study on midazolam in rats. Pharmacometrics 1985; 29: 959
- Vree T. B., Baars A. M., Booij L. H. D., Driessen J. J. Simultaneous determination and pharmacokinetics of midazolam and its hydroxymetabolites in plasma and urine of man and dog by means of high performance liquid chromatography. Arzneimittel-Forschung 1981; 31: 2215–2219